Monopar Therapeutics Inc. (MNPR) Stock Overview
Explore Monopar Therapeutics Inc.’s financial performance, market position, analyst ratings, and future outlook.
Monopar Therapeutics Inc. (MNPR)
Key Financials
Key Financials
Market Cap
742.4M
P/E Ratio
-46.92
EPS (TTM)
$-2.17
ROE
-0.13%
MNPR Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Monopar Therapeutics Inc. (NASDAQ: MNPR) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B, Monopar Therapeutics Inc.'s NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of MNPR on the NASDAQ shows an RSI of 49.93, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $101.83 for the NASDAQ listing.
Key metrics behind Monopar Therapeutics Inc.'s NASDAQ-traded stock include a P/E ratio of -46.92 and a market capitalization of 742.4M. Combined with our AI analysis, these give both institutional and retail investors a clear view of MNPR on the NASDAQ.